Pricing Policies Should Fit Arc, Not Spike, New PhRMA CEO Says
This article was originally published in The Pink Sheet Daily
Drug spending has jumped temporarily, Stephen Ubl says, but policy should reflect the long-term trend.
You may also be interested in...
Pharmacy benefit manager's anti-Daraprim effort signals new direction in pricing battles, but the strategy can only be used in limited circumstances.
Steve Ubl has led AdvaMed for 10 years, raising profile of device industry on Capitol Hill and executing well-regarded public relations campaign of the kind the drug industry might need as it enters political maelstrom on pricing.
Horizon CEO says safety trial will be conducted in a larger patient population following discussions during the US FDA advisory committee meeting.